Ensocell is a biotechnology company founded in 2023 and based in Cambridge, England. It focuses on applying spatial-omics and artificial intelligence/machine learning (AI/ML) technologies to therapeutic development, specifically targeting autoimmune, inflammatory, and fibrotic diseases.
The company's core technical work involves single-cell and spatial genomics, computational biology, and machine learning, including the development of GenAI models. Its primary product is the ENSIGHT platform, a proprietary system that integrates large-scale human single-cell and spatial genomics datasets with advanced machine learning algorithms. The platform is designed to identify disease intervention points and therapeutic targets at high cellular resolution.
Ensocell has secured $16.3 million in seed funding to support its research and platform development in the drug discovery space.
